Delving into the Latest Updates on Pentetate Zinc Trisodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Pentetate zinc trisodium (JAN), Zinc Trisodium Pentetate, Zn-DTPA

+ [4]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Poisoning

Inactive Indication

Metal Metabolism, Inborn Errors

Originator Organization

hameln pharma plus GmbH

Active Organization

Nihon Medi-Physics Co., Ltd.

Inactive Organization

hameln pharma plus GmbH

Drug Highest PhaseApproved

First Approval Date

United States (11 Aug 2004),

Metal Metabolism, Inborn Errors

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H18N3NaO10Zn

InChIKeyCRZKKCAXPUSAHT-UHFFFAOYSA-I

CAS Registry11082-38-5

The study aims at gathering additional data on the safety and effectiveness of using intravenous administration of the drugs Ca-DTPA/Zn-DTPA to remove the heavy metal gadolinium from the bodies of patients who have retained it and developed symptoms of Gadolinium Deposition Disease following an MRI in which a gadolinium-containing contrast agent was utilized. The outcome data will include measures of symptom relief after as many as six paired Calcium-DTPA/Zinc-DTPA chelation treatments. The study also aims at gathering additional data before and after DTPA treatment regarding levels of certain cytokines in the patients' blood that have been reported to be abnormally elevated in patients with retained gadolinium.

Start Date11 Apr 2023

Sponsor / Collaborator

Stanford University

NCT02947022

/ TerminatedPhase 1/2IIT

Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

Purpose: There are two goals we have for this prospective single arm study; to see an increase in the amount of gadolinium in 24 hour urine collection following each infusion treatment with Calcium and Zinc DTPA, and to see a reduction or elimination of gadolinium deposition disease (GDD) symptoms.
Participants: Twenty (20) patients who are suffering from gadolinium deposition disease (GDD)
Procedures: Over a series of three (3) treatment time-points patients will be treated with IV Ca-DTPA on day one, and Zn-DTPA on day two.

Start Date01 Oct 2016

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+1]

100 Clinical Results associated with Pentetate Zinc Trisodium

Login to view more data

100 Translational Medicine associated with Pentetate Zinc Trisodium

Login to view more data

100 Patents (Medical) associated with Pentetate Zinc Trisodium

Login to view more data

78

Literatures (Medical) associated with Pentetate Zinc Trisodium

01 May 2021·Journal of the Science of Food and Agriculture

Optimum Olsen Phosphorus/Zinc_DTPA ratio for the initial growth of maize in agricultural soils of the Mediterranean region

Article

Author: del Campillo, María Carmen ; Sacristán, Daniel ; González‐Guzmán, Adrián ; Torrent, José

AbstractBACKGROUNDZinc (Zn) deficiency in crops is commonly aggravated by high levels of phosphorus (P) in soil. In this work, the initial performance of pot‐growing maize in response to the available P and Zn in soils with low available Zn and to the application of P and Zn fertilizers was investigated.RESULTSThe soils (six non‐calcareous and 14 calcareous) ranged widely in available P (Olsen P: 5.5–37.9 mg kg−1), were poor in available Zn [diethylenetriaminepentaacetic acid‐extractable Zn (ZnDTPA): 0.20–0.84 mg kg−1] and had an Olsen P/ZnDTPA ratio of 13 to 111 mg mg−1. Soil P application generally increased aerial dry matter (ADM) yield; Zn increased ADM yield mostly when applied in combination with P; and the sole application of Zn increased yield only in a soil with a high (28 mg kg−1) Olsen P and a low (0.36 mg kg−1) ZnDTPA. The increase in ADM yield resulting from optimal application of P and/or Zn to the soil was modest in soils where the Olsen P/ZnDTPA ratio was 30–60 and Olsen P was >14 mg kg−1. Zinc uptake by the control plants was correlated with the ZnDTPA of the soil. For a certain ZnDTPA value, the level of plant available Zn was higher in non‐calcareous than in calcareous soils.CONCLUSIONSoil application of fertilizer P and Zn, in soils with low levels of available Zn, should not only aim at increasing the available P and Zn levels but also balancing them at the appropriate Olsen P/ZnDTPA ratio, which was found to lie in the 30–60 range in the present study. © 2020 Society of Chemical Industry

01 Feb 2020·Health Physics

Chelation Modeling: The Use of Ad Hoc Models and Approaches to Overcome a Dose Assessment Challenge

Review

Author: Poudel, Deepesh ; Dumit, Sara ; Klumpp, John A. ; Waters, Tom L. ; Bertelli, Luiz

AbstractChelating agents are administered to treat significant intakes of radioactive elements such as plutonium, americium, and curium. These drugs may be used as a medical countermeasure after radiological accidents and terrorist acts. The administration of a chelating agent, such as Ca-DTPA or Zn-DTPA, affects the actinide's normal biokinetics. It enhances the actinide's rate of excretion, posing a dose assessment challenge. Thus, the standard biokinetic models cannot be directly applied to the chelation-affected bioassay data in order to assess the radiation dose. The present study reviews the scientific literature, from the early 1970s until the present, on the different studies that focused on developing new chelation models and/or modeling of bioassay data affected by chelation treatment. Although scientific progress has been achieved, there is currently no consensus chelation model available, even after almost 50 y of research. This review acknowledges the efforts made by different research groups, highlighting the different methodology used in some of these studies. Finally, this study puts into perspective where we were, where we are, and where we are heading in regards to chelation modeling.

04 Mar 2019·Inorganic Chemistry

3-Hydroxy-2-Pyrrolidinone as a Potential Bidentate Ligand for in Vivo Chelation of Uranyl with Low Cytotoxicity and Moderate Decorporation Efficacy: A Solution Thermodynamics, Structural Chemistry, and in Vivo Uranyl Removal Survey

Article

Author: Wang, Shuao ; Liu, Yong ; Wan, Jianmei ; Chen, Lanhua ; Wang, Xiaomei ; Wang, Jianqiang ; Wu, Suqiang ; Shi, Cen ; Diwu, Juan ; Guan, Jingwen

Uranium poses a threat for severe renal and bone damage in vivo. With the rapid development of nuclear industry, it is more urgent than ever to search for potential in vivo uranium chelators. In this work, 3-hydroxy-2-pyrrolidinone (HPD) is investigated as a new potential uranium decorporation ligand. The potentiometric titration measurements were carried out, and the stability constants were determined to be log β₁₁₀ = 10.5(7), log β₁₂₀ = 20.7(9), and log β₁₃₀ = 28.2(4). The species distribution diagram shows that nearly all uranyl is complexed by HPD at pH 7.4 under the defined condition. A single crystal of uranyl and HPD complexes, [(UO₂)₃O(H₂O)₃(C₄H₆NO₂)₃]·NO₃·12H₂O (uranyl-HPD), was obtained via an evaporation method. The overall structure of uranyl-HPD is a trimer that consists of three uranyl units and three HPD ligands. The uranyl unit is equatorially coordinated by three oxygen atoms from two HPD agents, one coordinated water molecule, and one μ₃-O atom that is shared by three uranyl units. The results of the cytotoxicity assay indicate that the ligand is less toxic than the chelators used clinically (i.e., DTPA-ZnNa₃ and 3-hydroxy-1,2-dimethyl-4(1 H)-pyridone (DFP)). The results of the uranium removal assay using the NRK-52E cell show that it could reduce as much as 58% of the uranium content at the cellular level. Furthermore, the in vivo uranium decorporation assays demonstrate that HPD can remove 52% of uranium deposited in the kidney but shows poor uranium removal efficacy in the bone.

100 Deals associated with Pentetate Zinc Trisodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09762	-	V03AB	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Poisoning	Japan	Nihon Medi-Physics Co., Ltd.	01 Jul 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02947022 (CTgov)	Phase 1/2	Cognitive Dysfunction \| Arthralgia \| Gadolinium deposition disease \| Headache	1	Calcium DTPA+Zinc DTPA	egmxvukksa(pvfjbqmhyz) = jpppcbsnzd gnbrddbsyw (xrzsocnodi, vjlwrdtkjf - voonznmlmp) View more	-	06 Apr 2018